Successful Treatment of Two Patients with Candida auris Candidemia with the Investigational Agent, Oral Ibrexafungerp (formerly SCY-078), from the CARES Study

Favourable Clinical Outcome of Two Patients with Candida spp. Spondylodiscitis treated with Oral Ibrexafungerp (formerly SCY-078) from the FURI Study

Use of Ibrexafungerp (formerly SCY-078) to Treat Severe Azole Refractory Esophageal Candidiasis. A Case Report from the Furi Study

Penetration of Ibrexafungerp (formerly SCY-078) versus Micafungin at the Site of Infection in an Intra-abdominal Candidiasis Mouse Model

Efficacy of Ibrexafungerp (formerly SCY-078) Against Pneumocystis Pneumonia in a Murine Therapeutic Model.

Ibrexafungerp: Activity against Pneumocystis

Ibrexafungerp (SCY-078): A First-in-Class, Orally-Bioavailable, Glucan Synthase Inhibitor has Fungicidal Activity Against C. auris, an Emerging Multidrug-Resistant Pathogen

Stephen Barat, Katyna Borroto-Esoda, David Angulo
MSGERC 2018
September 2018

Ibrexafungerp (formerly SCY-078) Displays Potent In Vitro Activity Against C. glabrata Isolates with Mutations in fks Genes

Stephen Barat, Katyna Borroto-Esoda, David Angulo
ESCMID ASM 2018
September 2018

Ibrexafungerp (formerly SCY-078), a Novel IV/Oral Triterpenoid Antifungal Treatment, is Not Embryo/Feto-toxic

Christina M. Carruthers, Stephen Barat, Porsha Thomas, Elias Lewis
IDSOG 2018
August 2018

SCY-078: A first-in-class, orally-bioavailable, glucan synthase inhibitor has broad spectrum activity against Candida, Aspergillus and Pneumocystis spp.

Stephen Barat, Katyna Borroto-Esoda, David Angulo
ISHAM 2018
June 2018